The relative contribution of the effector molecules produced by T cells to tumour rejection is unclear, but interferon-γ (IFNγ) is critical in most of the analysed models 
The contribution of T-cell effector molecules to tumour rejection has mainly been studied in models of low tumour burden with little tumour stroma 1, 9 . For IFNγ -mediated effects, various cell types have been suggested as targets, such as the cancer cells themselves, macrophages, fibroblasts, monocytes or endothelial cells [10] [11] [12] [13] [14] [15] [16] [17] [18] . Most cells of the body express the IFNγ receptor (IFNγ R). IFNγ inhibits neoangiogenesis and prevents the development of tumours from inoculated cancer cells 12, 13 , but the effects of IFNγ on blood vessels of large established tumours are poorly understood. As human cancers are usually at least 1 cm in diameter when they are first detected, studying the effects of IFNγ on the vasculature of such tumours is clinically relevant. We transduced the fibrosarcoma cell line MCA313, derived from a methylcholanthrene-treated IFNγ R-deficient C57BL/6 (IFNγ R − ) mouse, with a retrovirus allowing doxycycline (dox)-mediated regulation of IFNγ expression (MCA313 IFNγ -IND ) 19, 20 (Fig. 1a) . MCA313
IFNγ-IND cells produced IFNγ upon treatment with dox (around 87 ng ml
), but not in its absence (Fig. 1b) . When IFNγ was induced in large MCA313
IFNγ -IND tumours in immunocompromised Rag-deficient (Rag − ) mice, serum levels reached a peak of around 10 ng ml −1 48 h after dox administration (Fig. 1c) . Induction of IFNγ in two-to threeweek-old large MCA313
IFNγ-IND tumours in C57BL/6 wild-type mice led to tumour regression, macroscopic and microscopic necrosis, and loss of tumour endothelial (CD31 + ) cells (Extended Data Fig. 1a-c) . Tumour regression was observed in wild-type but not in IFNγ R − mice (Extended Data Fig. 1a ). MCA313
IFNγ -IND tumours grew with similar kinetics and regressed similarly upon IFNγ induction in wild-type and Rag − mice, indicating their low immunogenicity (Extended Data  Fig. 1a ). To determine whether dox-induced IFNγ levels were comparable to those achieved by antigen-specific T cells that rejected established tumours of a similar size, we treated Rag − mice bearing 16.113 adenocarcinomas with CD8 + T cells, which are specific for SV40 large T antigen expressed by 16.113 cells (TCR-I T cells), and determined IFNγ serum levels 3-7 days after T-cell transfer. On day 4, around 13 ng ml
IFNγ was detected (Fig. 1c ) and tumours were subsequently rejected (Extended Data Fig. 1d ). Thus, IFNγ expression in large MCA313 IFNγ -IND tumours was comparable to that of effector T cells during tumour rejection and was sufficient to induce tumour regression, when only tumour stroma, and no cancer cells, could respond to IFNγ . Similarly, IFNγ induction in large IFNγ-insensitive 16.113-999
IFNγ -IND adenocarcinomas resulted in tumour regression and a reduction in tumour endothelial cells (Extended Data Fig. 1e-g ).
To identify the target stromal cells of IFNγ , we generated mice with exclusive IFNγ R expression in defined cell types. In these mice, the Ifngr1 transgene is linked to a GFP reporter gene by an internal ribosome entry site (IRES) and separated from a ubiquitous promoter by a Cre-recombinase-excisable stop cassette (pCAG loxP Stop loxP -IFNγ R-IRES-GFP, denoted hereafter as PIG mice; Fig. 1a , Extended Data Fig. 2a) . The mice were crossed to IFNγ R − mice to inactivate the endogenous Ifngr1 gene (PIG ΔIFNγ R ). Expression of the Cre recombinase in fibroblasts from PIG ΔIFNγ R mice led to IFNγ R (CD119) and GFP expression (Extended Data Fig. 2b ). IFNγ exposure caused upregulation of major histocompatibility complex I (MHC-I) comparable to wild-type fibroblasts, demonstrating the function and tight regulation of IFNγ R (Extended Data Fig. 2c ). We generated PIG (Fig. 2a-c) . Thus, exposing exclusively myeloid cells in established tumours to IFNγ does not lead to cancer regression.
We generated PIG ΔIFNγ R mice expressing FSP-Cre (PIG FSP-Cre mice) in which one fourth of tail fibroblasts and most haematopoietic cells, but not endothelial cells, were GFP + and therefore expressed IFNγR (Extended Data Fig. 3b, Supplementary Table 1a) . In MCA313 Fig. 3d ). Thus, response to IFNγ by tumour-associated fibroblasts, T cells or haematopoietic cells was not sufficient for IFNγ -induced tumour necrosis or regression.
We next analysed mice with selective IFNγ R expression in endothelial cells using PDGFB-CreER-IRES-GFP mice. Because these mice, in which recombination is tamoxifen-inducible in PDGFB + cells, and PIG ΔIFNγ R mice both carry GFP reporter genes, recombination was analysed in tamoxifen-treated PDGFB-CreER-IRES-GFP × Rosa26-RFP mice bearing large MCA313
IFNγ -IND tumours. Around 75.4% of tumour endothelial cells (CD31 + CD146 + ) had recombined, indicated by RFP expression (Extended Data Fig. 4a, b) . To avoid confounding effects by endogenous IFNγ (Extended Data Fig. 4c-g ), experiments were performed in PIG ΔIFNγ R × PDGFB-CreER-IRES-GFP × IFNγ − (PIG PDGFB-Cre-ΔIFNγ ) transgenic mice, which are deficient in IFNγ and IFNγ R expression and allow selective induction of IFNγ R expression in endothelial cells. GFP was almost exclusively expressed in tumour endothelial cells and faithfully monitored IFNγ R expression (Extended Data Fig. 5a, b) . The few GFP + CD11b + cells that were present did not respond to IFNγ with inducible nitric oxide synthase induction (Supplementary Table 1b Fig. 2g-i) . Following regression, tumours slowly resumed growth (Fig. 2i) . However, these tumours contained large central necrotic areas with viable cells at the rim (Extended Data Fig. 5d, e) . As opposed to endothelial cells without IFNγ induction, endothelial cells in tumours exposed for around 50 days to IFNγ were mostly GFP − , suggesting a strong selective pressure against IFNγR-expressing endothelial cells (Fig. 2j ). In line with this assumption, tumours grown for 50-100 days in PIG PDGFB-Cre or PIG CMV-Cre mice still produced inducible IFNγ in vitro (Extended Data Fig. 5f ). After five days of IFNγ exposure, endothelial cells (CD31
tumours of all of the mice investigated in this study were reduced by 80-90% only in tumours from mice containing endothelial cells that could respond to IFNγ (Fig. 2k) . To determine whether T-cell-derived IFNγ similarly affects endothelial cells, Rag − mice bearing 16.113 tumours were treated with IFNγ-competent or IFNγ-deficient TCR-I CD8 + T cells. Five days after T-cell transfer, we found a significantly lower number of endothelial cells in tumours treated with wild-type T cells than in those treated with IFNγ-deficient T cells (Extended Data  Fig. 1h ). IFNγ R responsiveness by tumour endothelial cells was necessary and sufficient for necrosis and tumour regression.
We intravitally imaged the same area of tumours that were growing behind a glass window over several days 22 . Fig. 6a ). Large vascularized J558L
IFNγ -GFP-IND tumours growing behind a window were imaged for 6 days following dox application. A GFP signal was observed 24 h after IFNγ -GFP induction, and vascular density decreased with a loss of smaller blood vessels and thinning of larger vessels (Fig. 3c) . At 48 h, blood vessels further decreased and were undetectable by 96 h of dox treatment. As shown by loss of cerulean signal, cancer cells were destroyed subsequent to blood vessel regression (Fig. 3d, Extended  Data Fig. 6b ). DiD-labelled erythrocytes, injected before imaging, did not leak from the tumour vessels during the entire longitudinal imaging. Instead, the blood flow ceased with progressing vessel regression (Supplementary Video 3) , showing that IFNγ induces tumour ischaemia.
We performed similar experiments with TNF, which is usually produced simultaneously with IFNγ by activated T cells. We generated cerulean + J558L TNF-GFP-IND cells with an inducible TNF-GFP fusion protein. J558L
TNF-GFP-IND cells produced 368 pg ml −1 biologically active TNF-GFP upon dox application (Fig. 3e, f) . Induction of TNF-GFP in established J558L
TNF-GFP-IND tumours growing in Rag − mice led to tumour regression (Extended Data Fig. 7a) . Imaging revealed notably different changes caused by TNF-GFP compared to IFNγ -GFP. The TNF-GFP signal was observed after 24 h and blood vessels did not become thinner but, if anything, wider ( Table 2) . Endothelial cells from all three tumours showed strong similarity in regulated genes. Genes associated with immune regulation and migration, for example, CXCL10 and CXCL11 (Extended Data Fig. 9c , Supplementary Table 2), were highly regulated. It is well-established that CXCL10 has anti-angiogenic effects on tumour blood vessels and is involved in physiological vessel regression, but it was unexpected that the tumour endothelial cells produce CXCL10 7,14-16 . We did not observe apoptosis-associated genes to be highly regulated in IFNγ -exposed endothelial cells (Supplementary Table 2 ). Rather, + pericytes did not decrease (Extended Data Fig. 10j , k), and we did not observe reduced co-localization with endothelial cells (Extended Data Fig. 10l ). Therefore, we assume that primarily pericyte-uncovered endothelial cells disappeared during the first 5 days of IFNγ exposure. IFNγ exposure led to rapid rounding and condensation of CD31 + and VE-cadherin + endothelial cells in MCA313 IFNγ -IND tumours, similar to that observed for regressing blood vessels during the ovarian cycle 24,25 (Extended Data  Fig. 10m ). In line with earlier studies on physiological blood vessel regression 25 , electron microscopy showed that the vessels were more frequently occluded upon IFNγ exposure (Extended Data Fig. 10n, o) . IFNγ also induced profound morphological changes of human umbilical vein endothelial cells in vitro without indication of apoptosis (Extended Data Fig. 9e, Supplementary Video 5) . In the J558L model, we confirmed reduction of endothelial (ERG + or CD31 + ) cells by IFNγ -GFP fusion protein (Extended Data Fig. 6c-g ) and found that TNF-GFP did not significantly change endothelial cell numbers during the first five days of cytokine exposure (Extended Data Fig. 7f, g ). Collectively, we observed a process, which involves lumen collapse/ vessel occlusion and progressive disappearance of first small and then large calibre vessels. These characteristics of controlled blood vessel regression suggest that IFNγ induces changes in the tumour vasculature similar to those observed during physiological blood vessel regression. Irf4, upregulated by IFNγ in tumour but not normal endothelial cells (Extended Data Fig. 9b, c, Supplementary Table 2 ), has not been reported to be induced by IFNγ in (tumour) endothelial cells and was induced in vitro by IFNγ in mouse endothelial cells (Extended Data  Fig. 9f ). Endothelial cells in large MCA313
IFNγ -IND tumours two days after IFNγ induction in Irf4-deficient mice revealed a more pronounced vessel reduction (Extended Data Fig. 9g, h ) and an increased number of apoptotic endothelial cells compared to those in wild-type mice Fig. 9i, j) , reminiscent of the protective role of IRF4 for neurons in ischaemia 26 . We showed that ischaemia, a pathological reaction, is beneficial in anti-tumour responses. Both, IFNγ and TNF destroy tumour blood vessels, yet by different mechanisms and with different consequences. IFNγ released by tumours did not lead to systemic toxicity in mice with selective IFNγ R expression on endothelial cells, as observed in wild-type mice, which is compatible with the observation that IFNγ , unlike TNF, does not induce necrosis in combination with bacterial products in the normal skin 27 . The early events induced by IFNγ in tumours resemble blood vessel regression in development, wound healing, ovary cycle and pregnancy-induced uterine vascular remodelling, the latter being regulated by IFNγ [6] [7] [8] 24, 25 . In conclusion, IFNγ and TNF, simultaneously produced by effector T cells, together have a strong effect on tumour blood vessels: (1) TNF bursts the tumour vessels and allows extravasation of infiltrating cells, and (2) IFNγ helps to prevent relapse by keeping the tumour in an ischaemic state, similar to that observed when these cytokines are targeted selectively to the vasculature 28 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper. IFNγ R-IRES-GFP. The retroviral vector plasmid for inducible IFNγ expression, pMOV-IFNγ , has been previously described 19 . To obtain pMOV-IFNγ -GFP and pMOV-TNF-GFP, cDNA sequences encoding for GFP-tagged mIFNγ or mTNF, including a glycine-serine-linker (G 4 S) 3 that is located between the cytokine and the GFP gene (replacing the cytokine 3′ untranslated region), were de novo synthesized by GeneArt (Regensburg, Germany). ) and CMVCre mice (strain number 006054) were obtained from the Jackson laboratories. TCR-I mice 32 are transgenic for a T-cell receptor specific for SV40 large T, epitope I, and were obtained from Jackson laboratories (strain number 005236) and crossed to a Rag − genetic background. FSP-Cre mice 33 were provided by E. G. Neilson (Northwestern University, Feinberg School of Medicine, Chicago) and were backcrossed for 10 generations to the C57BL/6 genetic background. Lys-Cre mice 34 backcrossed to C57BL/6 genetic background (N10) were obtained from S. Fillatreau (German Centre for Rheumatology Research, Berlin). PDGFB-CreER-IRES-GFP mice 35 were backcrossed for 10 generations to the C57BL/6 genetic background. To obtain mice with cell-type-specific expression of the IFNγ R, PIG mice were crossed to the respective Cre strain (CMV-Cre, Lys-Cre, FSP-Cre, PDGFB-CreER-IRES-GFP) and to IFNγ R − mice. PIG ΔIFNγ R × PDGFB-CreER-IRES-GFP were further crossed to IFNγ − mice. Mice used in experiments were heterozygous for the PIG and Cre alleles and homozygous for the IFNγ R − (and IFNγ − ) allele. Rosa26-tdRFP mice were generated on the C57BL/6 genetic background 36 and were crossed to PDGFB-CreER-IRES-GFP mice. Irf4 − mice 37 were backcrossed for 10 generations to the C57BL/6 genetic background. Irf4
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WT/− and Irf4 − were obtained by breeding Irf4 − male and Irf4 WT/− female mice. Male and female mice aged between 6-24 weeks were used and matched in experiments. All animal experiments were conducted in accordance with institutional, state, and federal guidelines and with permission of the local animal ethics committee of the LAGeSo, Berlin. Effect and sample size estimates were done and included in animal experiment applications. At any signs of illness (lethargy, hunched posture, scruffy coat, social isolation, inactivity or weight loss) mice were taken out of the experiment. All animals used for experiments are reported. No randomization was performed and the investigators were not blinded to allocation during experiments and outcome assessment. Genotyping. The PIG transgene was identified by PCR with primers specific for the stop cassette (chloramphenicol acetyltransferase gene) 5′ -CAGTCAGTTG CTCAATGTACC-3′ and 5′ -ACTGGTGAAACTCACCCA-3′ and the GFP gene 5′ -AAGTTCATCTGCACCACCG-3′ and 5′ -TCCTTGAAGAAGATGGTGCG-3′ . The endogenous Ifngr1 gene was detected with a forward primer specific for exon 4: 5′ -ATGCAACGGTTTCCACCCCC-3′ , and a reverse primer in intron 4: 5′ -CCAGT CATAGCCGAATAGCC-3′ . Ifngr1
− gene was detected with a forward primer specific for exon 4 (as above) and a reverse primer specific for the neomycin resistance gene 5′ -CCACCTCAGCACTGTCTTCA-3′ . IFNγ − mice were genotyped using the primers: oIMR6218 5′ -CCTTCTATCGCCTTCTTGACG-3′ , oIMR8284 5′ -AGAAGTAAGTGGAAGGGCCCAGAAG-3′ and oIMR8285 5′ -AGGGAAACTGGGAGAGGAGAAATAT-3′ . Rosa26-RFP mice were genotyped by PCR using primers 5′ -AAGACCGCGAAGAGTTTGTCC-3′ , 5′ -TAAGCCTGCCCAGAAGACTCC-3′ and 5′ -AAGGGAGCTGCA GTGGAGTA-3′ . The PDGFB-CreER-IRES-GFP transgene was detected using primers 5′ -GCCGCCGGGATCACTCTCG-3′ and 5′ -CCAGCCGCCGTCGC AACTC-3′ . All other Cre-transgenic mice (Lys-Cre, FSP-Cre and CMV-Cre) were genotyped by using the generic Cre-PCR from the Jackson labs with the primers: oIMR1084 5′ -GCGGTCTGGCAGTAAAAACTATC-3′ and oIMR1085 5′ -GTGAAACAGCATTGCTGTCAC TT-3′ . The genotypes of Rag − and TCR-I mice were confirmed by flow cytometry of peripheral blood mononuclear cells staining for T cells and B cells. The genotype for PIG × CMV-Cre, Lys-Cre, FSP-Cre, PDGFB-CreER-IRES-GFP was confirmed by flow cytometry assessing GFP. ) and dispase (1 mg ml −1 ) at 37 °C. Digestion was stopped by changing the medium (DMEM, 10% FCS). To generate immortalized fibroblasts from PIG mice, primary fibroblast cultures were transfected with the plasmid pCMV-Tagori 40 and with the plasmid pBabe-puro using Lipofectamine 2000 (Life Technologies), according to the manufacturer's instructions. Transfected fibroblasts were selected using 1 μ g ml −1 puromycin. To rule out bacterial products synergizing with TNF, J558L cells were tested for the presence of mycoplasma by PCR using the primers: 5′ -TGCACCATGTGTCACTCTGTTAACCTC-3′ and 5′ -GGGAGCAAACAGGATTAGATACCCT-3′ . No commonly misidentified cell line was used in the study. MCA313 are fibrosarcoma, J558L plasmocytoma and 16.113 are carcinoma cells that were distinguished by morphology in cell culture. No other authentication was used. Culture and imaging of HUVECs. Donor-pooled human umbilical vein endothelial cells (HUVECs; PromoCell, GmbH) were cultured in Endothelial Growth Medium 2 (Lonza, Ltd) according to the manufacturer's instructions for a maximum of five passages. For immunofluorescence and time lapse experiments, cells were plated on 18-mm coverslips or in Nunc Laboratory-Tek chambered coverglass 1.5 (ThermoFisher Scientific, Inc.) coated with 10 μ g ml −1 bovine plasma fibronectin (Sigma-Aldrich, Co. Llc., F1141). Cells were treated with recombinant human IFNγ (PeproTech) every 24 h for a total of 4 days. To stain actin filaments for live cell experiments, 250 nM SiR-Actin was added to the cells 1 h before the start of the imaging. For immunofluorescence analysis of HUVECs, cells were fixed and permeabilized for 1 min with 0.3% glutaraldehyde (EM Grade, Electron Microscopy Sciences), 0.25% Triton X-100 in cytoskeleton buffer (CB: 10 mM MES, pH 6.1, 150 mM NaCl, 5 mM EGTA, 5 mM glucose, 5 mM MgCl 2 ) followed by a second fixation step with 2% paraformaldehyde (Electron Microscopy Sciences) in CB for 10 min. The sample was quenched with 0.1% NaBrH 4 for 7 min and washed three times with PBS for 10 min. The sample was incubated in blocking buffer (3% BSA in PBS) for 1 h and stained overnight with rabbit polyclonal anti-human VE-cadherin antibody (Abcam, ab33168) in blocking buffer. The sample was then incubated for 1 h with donkey anti-rabbit IgG conjugated to Alexa Fluor 647 and 250 nM phalloidin conjugated to Alexa Fluor 488 (ThermoFisher Scientific, Inc.). Samples were mounted in Abberior Mount Solid mounting media (Abberior, GmbH). Imaging of HUVECs was performed on LSM 780 confocal microscope with Plan Apochromat 63× NA 1.4 Oil objective (Carl Zeiss). Time-lapse series with reflection-based autofocus were acquired using a custom-written Visual Basic macro (A. Politi and J. Ellenberg, EMBL Heidelberg), acquiring at least three positions per experiment per condition. z-stacks covering the entire cell volume were acquired and maximum intensity projected. Live imaging was performed at 37 °C under 5% CO 2 . Cytokine analysis. 2 × 10 5 MCA313
IFNγ -IND , J558L
TNF-GFP-IND , J558L
IFNγ -GFP-IND or 16.133-999 IFNγ-IND cells per ml were cultured for 48 h without or in the presence of 10, 50, or 100 ng ml −1 dox (Sigma Aldrich). Culture supernatants were analysed by IFNγ -or TNF-specific ELISA according to the manufacturer's (OptEIA; BD Biosciences) recommendation. TNF biological activity of the TNF-GFP fusion protein was analysed by an L929 cytotoxicity assay. L929 cells were seeded at 3.5 × 10 4 cells in 96 wells in RPMI, 2% FCS and cultured overnight. Then, 2 μ g ml 
, three replicates were tested per plate. To evaluate the bioactivity of the IFNγ -GFP fusion protein, 10 6 B16-F10 cells were cultured in 5 ml RPMI 1640 medium 10% FCS containing either recombinant IFNγ or IFNγ -GFP at a concentration of 1 ng ml −1
. After 48 h, MHC-I upregulation was analysed by flow cytometry. Blood samples were collected from the facial vein using a sterile lancet. Blood was allowed to agglutinate and then centrifuged for 20 min at 4 °C. Serum samples were aliquoted and stored at − 80 °C. To determine serum IFNγ levels, 20 μ l of 1:5 diluted serum was analysed using the cytometric bead array from eBioscience (Procartaplex) according to the manufacturer's instructions. Tumour experiments. or J558L IFNγ -GFP-IND cells were injected subcutaneously into the right flank of the mice. Tumours were measured 2-3 times weekly in three perpendicular diameters using a calliper, and tumour volume was calculated using the ellipsoid volume formula (π /6 × a × b × c). According to the animal application approved by the local ethics committee (LAGeSo Berlin), animals were taken out of the experiment, if tumours reached an average diameter of 1.5-2 cm. In none of the experiments, a tumour reached a larger size. Mice with tumour necrosis were observed daily and monitored for humane endpoint criteria (lethargy, hunched posture, scruffy coat, social isolation, inactivity or weight loss), and these exclusion criteria were not detected in any case. Dox was continuously administered by adding 1 mg ml −1 dox to light-protected drinking water (supplemented with 20 mg ml −1 glucose). Tamoxifen was administered in chow at 400 mg kg −1 (TAM400, LASvendi) three days before tumour cell transplantation as indicated. Before mice were exposed to tamoxifen chow, they were administered for 10 days soy-free chow from LASvendi to exclude effects from phytoestrogens.
In experiments described in Fig. 1f and Extended Data Fig. 1a (left panel), dox was administered in 48 h intervals (48 h on dox, 48 h on water). In intravital imaging experiments, dox was administered by daily bolus injection of 10 μ g i.p. For adoptive T-cell therapy, 10 6 16.113 cells were subcutaneously injected into Rag Potential immunogenicity of transgenes used in this study was excluded by experiments showing that MCA313 IFNγ -IND tumours grew and regressed after IFNγ induction with the same kinetics in wild-type and Rag − mice (Extended Data Fig. 1a ) and, furthermore, cells expressing the rtTA protein were not eliminated even after 100 days in fully immunocompetent mice (Extended Data Fig. 5f ). Scale bars for tumour pictures were inserted based on the calliper measurements of the day the picture was taken. Wound healing experiments. 10 6 MCA313 IFNγ -IND cells were injected subcutaneously into the right flank of indicated mice. After one week (tumour size approximately 50 mm 3 ), mice were anaesthetized, and a wound of 5 mm in diameter was made on the back of the mice using a biopsy punch. For the first 48 h, analgesia was administered. Mice were inspected every day. The wound healing process was recorded by taking photos and by measuring the diameter of the wound in two perpendicular axes using a calliper. Gene expression analysis. Tumour endothelial cells (CD31 + CD146 + ) were isolated by fluorescence-activated cell sorting into RNAzol. cDNA was synthesized from ~ 500 pg total RNA according to the standard Affymetrix protocol GeneChip WT Pico Kit (P/N 902623) by using the Affymetrix T7 RNA polymerase promoter which is attached to random primers. Pre-IVT was performed with 12 amplification cycles. Then, ss-cDNA was fragmented and biotinlabelled according to Affymetrix recommendations. Fragmented cDNA (3.8 μ g) was hybridized to MOGENE 2.0 ST arrays. Arrays were washed and stained in the Affymetrix Fluidics Station 450 and further scanned using the Affymetrix GeneChip Scanner 3000 7G. Software: Affymetrix GeneChip Command Console Version 4.0. The image data were normalized and quality controlled with the Affymetrix Expression Console Software Version 1.4. The microarray data were deposited in the GEO data repository under the accession number GSE94504.
The bioinformatics analysis of the gene expression data was carried out with R BioConductor, to quantify the gene expression changes and normalize array intensity values for the comparison between the samples we used 'rma' function from 'oligo' package (target = 'probeset' parameter was used). Manufacturer's probe identifiers were converted to mouse gene names with 'mogene20stprobeset.db' annotation. After background subtraction and quantile normalization each gene intensity is determined as median of probe set intensities. log fold changes are computed from the average across replicates. For MCA313
IFNγ -IND data from 24 h and 48 h after induction were so consistent that they could be regarded as replicates (data not shown). Differential expression analysis was carried out with 'limma' package by computing moderated t-statistics and Benjamini-Hochberg adjusted P values. Number of replicates analysed were: MCA313 , 24 h, n = 2; normal kidney, 0 h, n = 3; normal kidney, 24 h, n = 3; wild-type T cells, 5 days, n = 3; IFNγ − T cells, 5 days, n = 5. Longitudinal imaging using window chambers. The procedures for surgical implantation of window chambers and longitudinal imaging are detailed elsewhere 22 . In brief, window chambers were implanted into mice, and mice were injected with 10 6 cancer cells. 13-18 days later, dox administration was started and continued throughout the experiment. For microscopic analysis, mice with window chambers were anaesthetized using isofluorane. The window was fastened to the main stage of the microscope using a custom-made holder. Intravital two-photon microscopy. 24 h before imaging procedure, 10 μ g dox was injected i.p. in 100 μ l PBS. In vivo multiphoton microscopy (IVMPM) of J558L
IFNγ -GFP-IND tumours engrafted in Rag − mice was performed while mice were anaesthetized with isoflurane. For IVMPM, an Ultima Multiphoton Microscopy System was used (Prairie Technologies). For imaging GFP, the excitation wavelength was set to l = 890 nm. Band-pass filters optimized for GFP (BP l = 525/50 nm) were used for detection. Collected single plane images were assembled to a 3D stack for each tumour in silico using Amira 3D software. Transmission electron microscopy. Tumour tissue was fixed by immersion in phosphate buffered 4% (w/v) paraformaldehyde and 1.25% (v/v) glutaraldehyde. Samples were post-fixed with 1% (v/v) osmium tetroxide, dehydrated in a graded series of ethanol, and embedded in the PolyBed 812 resin (Polysciences, Inc., Germany).
Ultrathin sections (60-80 nm) were stained with uranyl acetate and lead citrate, and examined at 80 kV with a Zeiss EM 910 electron microscope (Zeiss, Oberkochen, Germany). Acquisition was done with a Quemesa CDD camera and the iTEM software (Emsis GmbH, Germany) and pictures were processed using Adobe Illustrator. Antibodies and staining reagents. The following anti-mouse antibodies were used for flow cytometry: NK1. anti-rat IgG and anti-rabbit IgG (Life Technologies) were used. Hoechst 33342 was used for staining nuclei. Flow cytometry. To analyse peripheral blood mononuclear cells, blood was taken from the facial vein using a sterile lancet. Erythrocytes were lysed using ACK lysis buffer (BD Biosciences). To exclude dead cells from analysis, 7-AAD or the fixable viability dye eFluor 450 were used. For staining of tumour stroma cells, tumours were isolated, cut into small pieces and digested for 1 h in RPMI 1640 medium containing 10 mg ml −1 collagenase II, 10 mg ml −1 dispase and 10 μ g ml −1 DNase I. Cells were washed in PBS and filtered over a 40 μ m nylon mesh. Fc-receptors were blocked with anti-CD16/32 blocking antibodies. To analyse tumour endothelial cells, we used an integrated magnetic enrichment, using anti-PE magnetic microbeads that were added to the sample of PE-positive cells (stained with CD31-PE-Cy7/CD146-PE) and were directly enriched before FACS analysis, as suggested for analysis of rare cells when using the MACSQuant analyser. 10 7 total cells from digested tumour material were stained with CD45.2, CD31, CD146 and live/dead cell exclusion. For IFNγ R (CD119) staining, a biotin-labelled anti-CD119 (2E2) antibody in combination with streptavidin-APC was used, the signal was subsequently enhanced by amplification using the FASER Kit-APC (Miltenyi Biotec) using streptavidin-anti-APC antibodies. Control staining was done without the primary antibody. For intracellular staining of IRF4, anti-IRF4 monoclonal antibody (Biolegend 646408) and the transcription factor staining kit (eBioscience 00-5523) was used. Nitric oxide synthase assay. For isolating macrophages, tumours were cut into small pieces and digested as described above. Cells were washed in PBS and filtered over a 40 μ m nylon mesh and labelled with anti-mouse CD11b MACS beads (Miltenyi Biotec). CD11b cells were purified by magnetic cell sorting (purity was > 90%). 4 × 10 5 CD11b cells were seeded in 12-well tissue culture plates. Cells were stimulated with 250 U ml −1 IFNγ for 24 h. The nitrite ion was measured in a Griess diazotization reaction using Griess reagent system (Promega) according to the manufacturer's instructions. In brief, 50 μ l of medium was mixed with 50 μ l of sulfanilamid solution and incubated for 10 min protected from light. Next, Griess reagent (N-(1-naphthyl)ethylenediamine) was added and incubated for another 10 min protected from light. Thereafter, absorbance was measured at 540 nm. Nitric oxide concentration was determined using the optical density value from the Nitric oxide standard curve and medium without standard (blank) was set as detection limit. Immunohistochemistry. Tumour tissues were fixed in 4% paraformaldehyde (Sigma Aldrich) containing 10% m/w sucrose overnight, incubated overnight in PBS-sucrose solution (25% m/w) and embedded in OCT-tissue tech (Sakura). 5 μ m sections were mounted on slides. Slides were treated with 0.2% galantine (Sigma Aldrich) and 0.2% Triton X-100 in PBS and additionally blocked with antibody diluent (Dako) for 1 h at room temperature. All antibody staining were performed in Dako antibody diluent solution. Primary antibodies were incubated overnight at 4 °C. After three washes with PBS, secondary antibodies were added for 1 h together with Hoechst 33342 (Sigma Aldrich) at room temperature. Negative controls were generated by staining with the secondary antibodies and Hoechst 33342 only. After staining, the slides were covered with slowfade (Life Technologies) and analysed with ObserverD.1 or LSM710 confocal microscopes (Zeiss). Haematoxylin and eosin (H&E) staining was performed on 5-μ m paraffin-embedded tissue sections. After deparaffinization and rehydration, sections were stained with haematoxylin (Gill no. 2) and eosin, covered with histomout and examined under an OberserverD.1 microscope with Zen software. For evaluation of erythrocytes, eosin fluorescence signals were captured and at least 60 high magnification fields from 3-4 tumours were analysed for each experimental group. Analysis was performed using ZEN software (Zeiss), ImageJ (version 1.49) or Imaris.
For VE-cadherin staining of tumour vasculature, tissue sections were fixed using 2% paraformaldehyde in PBS for 15 min at room temperature followed by three washes for 5 min with PBS and 10 min incubation in ice-cold methanol and another three washes for 5 min with PBS. Image IT enhancer was employed for 30 min at room temperature followed rinsing in PBS and one wash for 5 min with PBS. Blocking solution (PBS containing 10% goat serum and 2.5% mouse serum; Sigma) was used for 1 h at room temperature before staining procedure was started using anti-CD31 and anti-VE-cadherin (eBioscience 14-1441-82) diluted 1:50 in blocking solution incubated on tissue sections over night at 4 °C in a wet chamber. Secondary antibodies diluted 1:100 in blocking solution containing Hoechst 33342 were incubated for 2-3 h at room temperature. Mowiol was used as mounting medium after three finalizing washing steps with PBS for 5 min at room temperature. Statistics. No statistical methods were used to predetermine sample size. To estimate the effect size for those experiments not involving animals and presented in the paper, one pilot experiment was performed. Then, usually a second experiment powered on what was observed in the pilot experiment was performed to attain significance and to test reproducibility. Data generally met the assumptions of the tests performed. The variance was in general similar between the groups that were being statistically compared and data met the assumptions of the tests. Statistical analysis was performed with GraphPad Prism 5.0. When comparing two groups, if not indicated otherwise, we used the two-tailed Mann-Whitney U-test. When comparing more than two groups, we used the one-way ANOVA. P values less than 0.05 were considered as significant, * P < 0.05, * * P < 0.01 and * * * P < 0.001. Data availability. The datasets generated during the current study are available from the corresponding author on reasonable request. The custom-written AFS Visual Basic macro for the time-lapse microscopy series with reflection-based autofocus was developed by A. Politi and J. Ellenberg (EMBL Heidelberg) and is available at http://www.ellenberg.embl.de/. The microarray data are available from the GEO data repository under the accession number GSE94504. c, d , Quantification of histological analysis for CD31 and cleaved caspase 3 (CC3) staining, respectively. Each dot represents one field of view analysed by ImageJ. e, Representative CD31 and CC3 staining before and 120 h after dox. f, Quantification of ERG + nuclei from immunohistology. g, Representative ERG staining without and 120 h after dox. Scale bars, 100 μ m. Three tumours with 4-6 fields of view were analysed. * * P < 0.01 and * * * P < 0.001. The number of mice, replications and sample size for each experiment are shown in Supplementary Table 3. 
